References
- Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020;76(4):489-500.
- NDA multidisciplinary review and evaluation {NDA 211415} {Quzyttir (cetirizine hydrochloride injection) for intravenous use}. U.S. Food and Drug Administration website. Accessed May 18, 2021.
- Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician. 2017;95(11):717-724.
- Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123.
- Zyrtec (cetirizine hydrochrloride) tablets and syrup for oral use. U.S. Food and Drug Administration website. Accessed May 18, 2021.
- Drug monograph: Quzyttir. Conduent website. Accessed May 18, 2021.
Explore This Issue
ACEP Now: Vol 40 – No 06 – June 2021Pages: 1 2 3 | Single Page
2 Responses to “Does New IV Urticaria Medication Offer Benefits Over Current Treatments?”
July 19, 2021
Dr. Joseph SachterExcellent review — as usual. Although I might use the intravenous preparation a little more frequently than “almost never’ (an unaccompanied patient who drove to themselves to the ED and might otherwise be ready for discharge a couple of hours after treatment initiation), the $300 a dose price is a dealbreaker.
This in turn brings up an interesting economic question. Wouldn’t TerSera (marketers of the drug) make more money overall if they charged less? Best analogy I can think of is a movie theatre charging $5 for a pint of spring water that costs them no more than a dime. Wouldn’t they sell at least five times more if they charged a dollar?
July 20, 2021
Ryan RadeckiI would imagine the price point for Quzyttir was thoughtfully selected from a team of analysts putting together a value-based price – potentially incorporating, perhaps, the revenue gain from reduced ED LOS if the drug were to offer some more rapid discharge, etc.